<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Aging</journal-id>
<journal-title-group>
<journal-title>Frontiers in Aging</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Aging</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2673-6217</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1765665</article-id>
<article-id pub-id-type="doi">10.3389/fragi.2026.1765665</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Phenotypic and functional heterogeneity of na&#xef;ve CD8<sup>&#x2b;</sup> T cells in human peripheral blood during aging</article-title>
<alt-title alt-title-type="left-running-head">Pangrazzi et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fragi.2026.1765665">10.3389/fragi.2026.1765665</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Pangrazzi</surname>
<given-names>Luca</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/984108"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/Validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualisation" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualisation/">Visualisation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Pehl</surname>
<given-names>Patrizia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Hoffmann</surname>
<given-names>Lotti</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Bachmann</surname>
<given-names>Martin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chelini</surname>
<given-names>Gabriele</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1535850"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Keller</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jenewein</surname>
<given-names>Brigitte</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cavinato</surname>
<given-names>Maria</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1699015"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weinberger</surname>
<given-names>Birgit</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/89125"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Institute for Biomedical Aging Research, University of Innsbruck</institution>, <city>Innsbruck</city>, <country country="AT">Austria</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>CNR Neuroscience Institute</institution>, <city>Pisa</city>, <country country="IT">Italy</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Luca Pangrazzi, <email xlink:href="mailto:luca.pangrazzi@uibk.ac.at">luca.pangrazzi@uibk.ac.at</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>&#x2020;</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-02">
<day>02</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>7</volume>
<elocation-id>1765665</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>12</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Pangrazzi, Pehl, Hoffmann, Bachmann, Chelini, Keller, Jenewein, Cavinato and Weinberger.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Pangrazzi, Pehl, Hoffmann, Bachmann, Chelini, Keller, Jenewein, Cavinato and Weinberger</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-02">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Na&#xef;ve CD8<sup>&#x2b;</sup> T cells are key players of adaptive immunity, but their heterogeneity and age-related changes are not fully understood. This study aimed to compare na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets defined by different combinations of markers, namely, N<sub>CCR7</sub> (CD45RA<sup>&#x2b;</sup>CCR7<sup>&#x2b;</sup>), N<sub>CD28</sub> (CD45RA<sup>&#x2b;</sup>CD28<sup>&#x2b;</sup>), N<sub>CD27</sub> (CD45RA<sup>&#x2b;</sup>CD27<sup>&#x2b;</sup>), and phenotypically most &#x201c;true-na&#xef;ve&#x201d;-like, N<sub>TN</sub> (CD45RA<sup>&#x2b;</sup>CCR7<sup>&#x2b;</sup>CD28<sup>&#x2b;</sup>CD27<sup>&#x2b;</sup>CD57<sup>&#x2212;</sup>). Peripheral blood was harvested from donors of various ages and the phenotype of the four subsets of na&#xef;ve CD8<sup>&#x2b;</sup> T cells was analyzed. N<sub>CD27</sub> and N<sub>TN</sub> cells showed similar phenotypes with low expression of differentiation markers, pro-inflammatory cytokines, and effector molecules. Furthermore, they exhibited optimal mitochondrial fitness, low senescence markers, reduced apoptosis, and high proliferation potential. Hierarchical clustering identified cluster one including N<sub>CD27</sub> and N<sub>TN</sub>, with lower expression of differentiation markers and pro-inflammatory molecules, and cluster 2, including N<sub>CCR7</sub> and N<sub>CD28</sub> cells, in which these parameters were more expressed. Age-related changes were observed in all subsets, although they were less pronounced for the N<sub>CD27</sub> and N<sub>TN</sub> subsets. Taken together, this study demonstrates significant heterogeneity among na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets, with N<sub>TN</sub> cells representing the most <italic>bona fide</italic> na&#xef;ve phenotype and N<sub>CD27</sub> showing a partially similar phenotype. These findings significantly enhance our understanding of na&#xef;ve CD8<sup>&#x2b;</sup> T cell biology and function.</p>
</abstract>
<kwd-group>
<kwd>adaptive immunity</kwd>
<kwd>aging</kwd>
<kwd>immunosenescence</kwd>
<kwd>na&#xef;ve T cells</kwd>
<kwd>T cells</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. The authors thank the University of Innsbruck (Austria) for providing financial support for this study.</funding-statement>
</funding-group>
<counts>
<fig-count count="9"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="35"/>
<page-count count="12"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Aging and the Immune System</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Aging is accompanied by thymic involution, a process in which the thymus undergoes progressive atrophy, structural alterations, as well as functional decline, leading to a significant decrease in the output of na&#xef;ve T cells (<xref ref-type="bibr" rid="B11">George and Ritter, 1996</xref>; <xref ref-type="bibr" rid="B28">Thomas et al., 2020</xref>). As the thymus involutes, na&#xef;ve T cell populations in the elderly are maintained by homeostatic proliferation of peripheral T cells (<xref ref-type="bibr" rid="B12">Kamimura et al., 2015</xref>). Alongside reduced na&#xef;ve T cell production, increased numbers of effector/memory T cells with features of terminal differentiation are present in old age (<xref ref-type="bibr" rid="B18">Pangrazzi et al., 2017a</xref>; <xref ref-type="bibr" rid="B20">Pangrazzi et al., 2020</xref>). Persistent antigenic stimulation, including chronic viral infections, supports the accumulation of late differentiated/senescent-like T cells, particularly within the CD8 compartment (<xref ref-type="bibr" rid="B17">Pangrazzi and Weinberger, 2020</xref>; <xref ref-type="bibr" rid="B2">Appay et al., 2011</xref>; <xref ref-type="bibr" rid="B19">Pangrazzi et al., 2017b</xref>). The composition of the na&#xef;ve CD8<sup>&#x2b;</sup> T cell compartment and its functionality are known to consistently change with aging, thus playing a determinant role in immunosenescence (<xref ref-type="bibr" rid="B8">Egorov et al., 2018</xref>). These alterations have been associated with impaired immune responses to novel antigens, therefore contributing to severity of infectious diseases in the elderly population (<xref ref-type="bibr" rid="B23">Seshadri et al., 2023</xref>). To achieve complete activation of na&#xef;ve and memory CD8<sup>&#x2b;</sup> T cells, costimulatory signals are required in addition to the first signal provided by the interaction of the T cell receptor (TCR) with the MHC/peptide complex. The best-defined co-stimuli involve the interaction between the co-stimulatory receptors CD28 and CD27 expressed by T cells and their ligands CD80/CD86 and CD70 on the surface of antigen-presenting cells (APCs) (<xref ref-type="bibr" rid="B15">Larbi and Fulop, 2014</xref>). After persistent antigenic stimulation and several cycles of activation, expression of both CD28 and CD27 is progressively downregulated on the surface of CD8<sup>&#x2b;</sup> T cells (<xref ref-type="bibr" rid="B15">Larbi and Fulop, 2014</xref>). In addition to CD28 and CD27, na&#xef;ve T cells express the lymph node homing receptor CCR7 and the CD45 isoform CD45RA (<xref ref-type="bibr" rid="B10">Geginat et al., 2003</xref>). Notably, Koch and colleagues defined the CD45RA<sup>&#x2b;</sup>CCR7<sup>&#x2b;</sup>CD27<sup>&#x2b;</sup>CD28<sup>&#x2b;</sup>CD57<sup>&#x2212;</sup> (N<sub>TN</sub>) subset as the most <italic>bona fide</italic> na&#xef;ve CD8<sup>&#x2b;</sup> T cell population (<xref ref-type="bibr" rid="B13">Koch et al., 2008</xref>). Although multiple markers have been proposed to define human na&#xef;ve CD8<sup>&#x2b;</sup> T cells, no universally accepted definition exists in the literature. This lack of consensus complicates comparisons across studies. Furthermore, no previous research has systematically evaluated and characterized the various existing definitions of na&#xef;ve CD8<sup>&#x2b;</sup> T cells in parallel.</p>
<p>In this work, we assessed the expression of molecules associated with CD8<sup>&#x2b;</sup> T cell differentiation, cytokines, effector molecules, as well as parameters defining mitochondrial fitness, oxidative stress, and senescence, in na&#xef;ve CD8<sup>&#x2b;</sup> T cells defined using four different combinations of markers. Furthermore, we measured DNA damage-induced apoptosis and proliferation potential of these subpopulations. Age-related changes in the phenotype of these na&#xef;ve subpopulations were additionally described.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Blood donors and isolation of PBMCs</title>
<p>Peripheral blood samples were obtained from systemically healthy individuals who did not suffer from diseases known to affect the immune system. Overall, our cohort included 60 donors, age range 21&#x2013;84, 28 males and 32 females. The number of donors used for each individual experiment is indicated in the figure legends. Purification of PBMCs from heparinized blood was performed by density gradient centrifugation (Lymphoprep, Stemcell). Freshly purified PBMCs were washed with RPMI 1640 medium supplemented with 100 U/mL penicillin, and 100&#xa0;&#x3bc;g/mL streptomycin (P/S, both Sigma-Aldrich) and finally resuspended in medium additionally supplemented with 10% fetal calf serum (FCS, Sigma-Aldrich, complete medium).</p>
</sec>
<sec id="s2-2">
<title>Cell culture and flow cytometry analysis</title>
<p>Flow cytometry experiments were performed in accordance with the &#x201c;Guidelines for the use of flow cytometry and cell sorting in immunological studies&#x201d; (<xref ref-type="bibr" rid="B4">Cossarizza et al., 2021</xref>). Immunofluorescence surface staining was performed by adding a panel of directly conjugated antibody to freshly prepared PBMCs. Dead cells were excluded from the analysis using a fixable viability dye (Zombie Aqua&#x2122; Fixable Viability Kit, Biolegend) or DAPI. After surface staining, cells were fixed and permeabilized using the Cytofix/Cytoperm kit (BD Pharmingen) for TNF, IFN&#x3b3;, and granzyme B (GrzB) or the eBioscience Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher Scientific) for Tbet and incubated with intracellular Abs. To analyze TNF and IFN&#x3b3; expression, PBMCs were previously stimulated for 4&#xa0;h at 37&#xa0;&#xb0;C 5% CO<sub>2</sub> with 30&#xa0;ng/mL PMA and 500&#xa0;ng/mL ionomycin in the presence of 10&#xa0;&#x3bc;g/mL Brefeldin A (BFA, Sigma&#x2013;Aldrich) or for 16&#xa0;h with 1&#xa0;&#x3bc;g/ml anti-CD3 &#x2b; 10&#xa0;&#x3bc;g/mL BFA. GrzB expression was assessed in unstimulated cells. Proliferation was measured after stimulation with 1&#xa0;&#x3bc;g/ml anti-CD3 or 1&#xa0;&#x3bc;g/ml PHA for 4&#xa0;days. Samples for flow cytometric analysis were measured using a BD LSR Fortessa X&#x2010;20 (BD Biosciences), and analysis was performed with FlowJo software (FlowJo, version 10.8.1). Antibodies used for this study are shown in <xref ref-type="table" rid="T1">table 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Flow cytometry antibody used for the study.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Antibody</th>
<th align="center">Fluorochrome</th>
<th align="center">Company</th>
<th align="center">Clone</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Caspase 3</td>
<td align="center">FITC</td>
<td align="center">BD Biosciences</td>
<td align="center">C92-605.rMAb</td>
</tr>
<tr>
<td align="center">CCR7</td>
<td align="center">PECy7</td>
<td align="center">BD Biosciences</td>
<td align="center">3D12</td>
</tr>
<tr>
<td align="center">CD158b</td>
<td align="center">PE</td>
<td align="center">BD Biosciences</td>
<td align="center">DX27</td>
</tr>
<tr>
<td align="center">CD158e1</td>
<td align="center">PE</td>
<td align="center">BD Biosciences</td>
<td align="center">DX9</td>
</tr>
<tr>
<td align="center">CD16</td>
<td align="center">APC</td>
<td align="center">Miltenyi</td>
<td align="center">REA423</td>
</tr>
<tr>
<td align="center">CD27</td>
<td align="center">BV421</td>
<td align="center">BD Biosciences</td>
<td align="center">M-T271</td>
</tr>
<tr>
<td align="center">CD27</td>
<td align="center">APC</td>
<td align="center">Miltenyi</td>
<td align="center">REA499</td>
</tr>
<tr>
<td align="center">CD27</td>
<td align="center">FITC</td>
<td align="center">Miltenyi</td>
<td align="center">REA499</td>
</tr>
<tr>
<td align="center">CD28</td>
<td align="center">APC-Cy7</td>
<td align="center">Miltenyi</td>
<td align="center">REA612</td>
</tr>
<tr>
<td align="center">CD3</td>
<td align="center">BV650</td>
<td align="center">BD Biosciences</td>
<td align="center">UCHT1</td>
</tr>
<tr>
<td align="center">CD45RA</td>
<td align="center">BV510</td>
<td align="center">Miltenyi</td>
<td align="center">REA1047</td>
</tr>
<tr>
<td align="center">CD56</td>
<td align="center">APC</td>
<td align="center">Miltenyi</td>
<td align="center">REA196</td>
</tr>
<tr>
<td align="center">CD57</td>
<td align="center">PE-CF 594</td>
<td align="center">BD Biosciences</td>
<td align="center">NK-1</td>
</tr>
<tr>
<td align="center">CD57</td>
<td align="center">UV</td>
<td align="center">BD Biosciences</td>
<td align="center">NK-1</td>
</tr>
<tr>
<td align="center">CD57</td>
<td align="center">BB515</td>
<td align="center">BD Biosciences</td>
<td align="center">NK-1</td>
</tr>
<tr>
<td align="center">CD8</td>
<td align="center">PerCP</td>
<td align="center">Biolegend</td>
<td align="center">SK1</td>
</tr>
<tr>
<td align="center">CD95</td>
<td align="center">BUV737</td>
<td align="center">BD Biosciences</td>
<td align="center">DX2</td>
</tr>
<tr>
<td align="center">CD94</td>
<td align="center">APC</td>
<td align="center">Miltenyi</td>
<td align="center">REA113</td>
</tr>
<tr>
<td align="center">CX3CR1</td>
<td align="center">APC</td>
<td align="center">Miltenyi</td>
<td align="center">REA385</td>
</tr>
<tr>
<td align="center">GrzB</td>
<td align="center">FITC</td>
<td align="center">Miltenyi</td>
<td align="center">REA226</td>
</tr>
<tr>
<td align="center">IFN&#x3b3;</td>
<td align="center">APC</td>
<td align="center">BD Biosciences</td>
<td align="center">B27</td>
</tr>
<tr>
<td align="center">NKp80</td>
<td align="center">APC</td>
<td align="center">Miltenyi</td>
<td align="center">REA845</td>
</tr>
<tr>
<td align="center">TNF</td>
<td align="center">PE</td>
<td align="center">BD Biosciences</td>
<td align="center">MAb11</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-3">
<title>Cellular senescence assay</title>
<p>Cellular senescence in na&#xef;ve CD8<sup>&#x2b;</sup> T cells was assessed using the Cellular Senescence Detection Kit&#x2010;SPiDER&#x2010;&#x3b2;Gal (Dojindo Molecular Technologies). Bafilomycin A1 was reconstituted in 30&#xa0;&#x3bc;L dimethyl sulfoxide (DMSO, Sigma Aldrich) and SPiDER&#x2010;&#x3b2;Gal in 20&#xa0;&#x3bc;L DMSO (<xref ref-type="bibr" rid="B21">Pangrazzi et al., 2025</xref>). PBMCs were incubated in complete medium with a 1:500 dilution of bafilomycin A1 for 1.5&#xa0;h at 37&#xa0;&#xb0;C 5% CO<sub>2</sub> before the addition of 1:1000 dilution SPiDER&#x2010;&#x3b2;Gal for another 30&#xa0;min. PBMCs were washed with PBS and afterwards incubated with surface Abs at 4&#xa0;&#xb0;C diluted in PBS.</p>
</sec>
<sec id="s2-4">
<title>Mitochondria assays</title>
<p>Total mitochondrial content was assessed in na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets within PBMCs using 100&#xa0;nM MitoTracker Deep Red FM and mitochondrial ROS with 100&#xa0;nM reduced MitoTracker Red CM-H2-XRos (both ThermoFisher Scientific). Mitochondrial membrane potential was assessed using 0.5&#xa0;&#x3bc;g/ml JC-1 (ThermoFisher Scientific). Derived PE/FITC mean fluorescence ratio was calculated using Flowjo and was normalised against Mitotracker Deep Red (DR) intensity. PBMCs were incubated in the presence of each dye as well as surface Abs for 20min at 37&#xa0;&#xb0;C 5% CO<sub>2</sub> and afterwards washed with PBS. Negative control samples (i.e., PBMCs stained with JC-1 in the presence of 5&#xa0;&#xb5;M FCCP to induce mitochondrial membrane potential depolarization) as well as positive controls (i.e., PBMCs stained with 5&#xa0;&#xb5;M oligomycin to induce mitochondrial membrane potential hyperpolarization) were additionally included. After the incubation, cells were washed with PBS and measured immediately at the flow cytometer.</p>
</sec>
<sec id="s2-5">
<title>Measurement of intracellular ROS</title>
<p>To assess intracellular ROS, PBMCs were incubated with the fluorescent dye dihydroethidium (DHE, Sigma-Aldrich) at a concentration of 50&#xa0;nM in complete RPMI for 20&#xa0;min at 37&#xa0;&#xb0;C 5% CO<sub>2</sub>. Cells were washed in PBS and measured at the flow cytometer.</p>
</sec>
<sec id="s2-6">
<title>Assessment of proliferation</title>
<p>Proliferation was measured after labelling of PBMCs with Cell Proliferation Dye eFluor&#x2122; 450 (CPD450, ThermoFisher Scientific) and stimulation with either 1&#xa0;&#x3bc;g/mL anti-CD3 Ab or 1&#xa0;&#x3bc;g/mL PHA (BD Biosciences) for 4 days. After incubation, cells were stained with surface Abs and measured by FACS. Results were displayed using the proliferation index (PI, calculated as <inline-formula id="inf1">
<mml:math id="m1">
<mml:mrow>
<mml:mrow>
<mml:mfenced open="[" close="]" separators="|">
<mml:mrow>
<mml:msub>
<mml:mi mathvariant="normal">&#x3a3;</mml:mi>
<mml:mrow>
<mml:mi>n</mml:mi>
<mml:mo>&#x3e;</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mi>n</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mn>2</mml:mn>
<mml:mi>n</mml:mi>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mrow>
<mml:mfenced open="[" close="]" separators="|">
<mml:mrow>
<mml:msub>
<mml:mi mathvariant="normal">&#x3a3;</mml:mi>
<mml:mrow>
<mml:mi>n</mml:mi>
<mml:mo>&#x3e;</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mi>n</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mn>2</mml:mn>
<mml:mi>n</mml:mi>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:math>
</inline-formula>) and percentage of proliferated cells (i.e., number of proliferating cells/total number of cells) &#x2a; 100.</p>
</sec>
<sec id="s2-7">
<title>Assessment of apoptosis and DNA damage</title>
<p>Apoptosis and DNA damage were assessed after incubation of PBMCs with 30&#xa0;&#x3bc;g/mL etoposide (Sigma&#x2013;Aldrich) for 1 day at 37&#xa0;&#xb0;C 5% CO<sub>2</sub>. Apoptotic cells were assessed after intracellular staining with caspase three or alternatively with 400&#xa0;nM Apotracker green (Biolegend) in the presence of surface Abs and DAPI. Early apoptotic cells were identified as Apotracker<sup>&#x2b;</sup> DAPI<sup>&#x2212;</sup> and late apoptotic cells as Apotracker<sup>&#x2b;</sup> DAPI<sup>&#x2b;</sup>. DNA damage was quantified after intracellular staining with anti-&#x3b3;H2AX pS139-FITC (REA502, Miltenyi) Ab.</p>
</sec>
<sec id="s2-8">
<title>Statistical analysis</title>
<p>Statistical significance was assessed using nonparametric Friedman test followed by Dunn&#x2019;s post hoc test, and Spearman correlations, as indicated in the figure legends. A p-value &#x3c;0.05 was considered significant. Both analyses were performed using the GraphPad 10.1 software. Cluster analysis and related statistics were performed using the JMPpro17 software (SAS Institute Inc., Cary, NC, 2023). Unsupervised clustering was carried out using the &#x2018;hierarchical clustering&#x2019; function embedded in JMP environment. The elbow method was used to determine the ideal number of clusters (<xref ref-type="bibr" rid="B29">Thorndike, 1953</xref>). Prior to the clustering, the sphericity assumption was confirmed using a Bartlett&#x2019;s test. The effect size and significant impact of immunological parameters on the clustering model was assessed using a multiple regression model controlling false-discovery rate. Differences in the frequency distributions of cell populations within clusters were evaluated using Fisher&#x2019;s exact test. Means &#xb1; SD are shown in each graph.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Differentiation markers, cytokines and effector molecules in N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells</title>
<p>To investigate the differentiation state of na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets, the expression of key T cell differentiation markers was measured in na&#xef;ve CD8<sup>&#x2b;</sup> T cells defined using CD45RA in combination with CCR7 (N<sub>CCR7</sub>), CD28 (N<sub>CD28</sub>), or CD27 (N<sub>CD27</sub>), as well as in phenotypically most &#x201c;true-na&#xef;ve&#x201d;-like CD45RA<sup>&#x2b;</sup>CCR7<sup>&#x2b;</sup>CD28<sup>&#x2b;</sup>CD27<sup>&#x2b;</sup>CD57<sup>&#x2212;</sup> (N<sub>TN</sub>) cells within PBMCs from donors of different age (<xref ref-type="fig" rid="F1">Figure 1</xref>). The gating strategy used to define the four subsets is reported in <xref ref-type="sec" rid="s12">Supplementary Figure S1</xref>. The expression of the chemokine receptor CX3CR1 increases during T cell differentiation (<xref ref-type="bibr" rid="B35">Zwijnenburg et al., 2023</xref>). When we measured CX3CR1 levels in the four na&#xef;ve subsets, it was the highest in the N<sub>CCR7</sub> subpopulation, and it significantly decreased in N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> cells (<xref ref-type="fig" rid="F1">Figure 1a</xref>). Representative FACS plots showing the levels of CX3CR1 in the four subpopulations is shown in <xref ref-type="sec" rid="s12">Supplementary Figure S2</xref>. The lowest expression was found in the N<sub>TN</sub> subset, although they were particularly low also in N<sub>CD27</sub>. Natural killer (NK) markers are known to increase with T cell differentiation and show the highest levels in terminally differentiated T cells (<xref ref-type="bibr" rid="B20">Pangrazzi et al., 2020</xref>; <xref ref-type="bibr" rid="B14">Koh et al., 2023</xref>). The expression of CD16, CD94, NKp80 and CD56 was assessed in the four na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets and was higher in the N<sub>CD28</sub> cells compared to the other na&#xef;ve subsets, slightly lower in N<sub>CCR7</sub>, and further decreased in the N<sub>CD27</sub> and N<sub>TN</sub> populations (<xref ref-type="fig" rid="F1">Figures 1B&#x2013;E</xref>). The NK inhibitory receptor CD158 (CD158b/CD158e1), which belongs to the killer-cell immunoglobulin-like receptor (KIR) family, was absent on N<sub>TN</sub> cells, while low but still detectable numbers of CD158<sup>&#x2b;</sup> cells were found in the other na&#xef;ve subsets (<xref ref-type="fig" rid="F1">Figure 1f</xref>). Relatively high levels of CX3CR1, CD16, and NKp80 were described in stem-like memory (T<sub>SCM</sub>, CD45RA<sup>&#x2b;</sup>CD27<sup>&#x2b;</sup>CCR7<sup>&#x2b;</sup>CD28<sup>&#x2b;</sup>CD95<sup>&#x2b;</sup>) cells (<xref ref-type="sec" rid="s12">Supplementary Figure Sa-c</xref>). Thus, N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> show unique expression of differentiation markers.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Differentiation markers in N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. Frequency of <bold>(a)</bold> CX3CR1<sup>&#x2b;</sup>, <bold>(b)</bold> CD16<sup>&#x2b;</sup>, <bold>(c)</bold> CD94<sup>&#x2b;</sup>, <bold>(d)</bold> NKp80<sup>&#x2b;</sup>, <bold>(e)</bold> CD56<sup>&#x2b;</sup>, <bold>(f)</bold> CD158b/CD158e1<sup>&#x2b;</sup> cells within N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. n &#x3d; 39 (CX3CR1, CD16, CD94, NKp80 and CD56) and n &#x3d; 34 (CD158b/CD158e1) in each subset. Friedman test, Dunn&#x2019;s post hoc test. &#x2a;p &#x3c; 0.05; &#x2a;&#x2a;p &#x3c; 0.01; &#x2a;&#x2a;&#x2a;p &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;p &#x3c; 0.0001. </p>
</caption>
<graphic xlink:href="fragi-07-1765665-g001.tif">
<alt-text content-type="machine-generated">Scatter plots a to f display the percentage of various markers within CD8+ T cell subsets. Each plot compares subsets \(N_{CCR7}\), \(N_{CD28}\), \(N_{CD27}\), and \(N_{TN}\). Markers include CX3CR1, CD16, CD94, NKp80, CD56, and CD158b/CD158e1. Significance levels are indicated by asterisks. Error bars represent standard deviation.</alt-text>
</graphic>
</fig>
<p>The production of cytokines and effector molecules is associated with T cell differentiation. We therefore investigated whether the expression of TNF, IFN&#x3b3;, and granzyme B (GrzB) may differ between the N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> subsets (<xref ref-type="fig" rid="F2">Figure 2</xref>). In both PMA/Ionomycin and anti-CD3 stimulated cells, TNF expression was highest in N<sub>CCR7</sub> cells, intermediate in N<sub>CD28</sub> and N<sub>CD27</sub> and lowest in the N<sub>TN</sub> population (<xref ref-type="fig" rid="F2">Figure 2a</xref>). Similar results were observed when IFN&#x3b3;, and GrzB levels were assessed (<xref ref-type="fig" rid="F2">Figures 2b,c</xref>). Higher expression of TNF, IFN&#x3b3;, and GrzB was present in the T<sub>SCM</sub> subpopulation (<xref ref-type="sec" rid="s12">Supplementary Figures S3d-f</xref>). Taken together N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells are different regarding their expression of differentiation markers and T cell cytokines, with N<sub>CD27</sub> being more like N<sub>TN</sub> cells.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Cytokines and effector molecules in N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. Frequency of <bold>(a)</bold> TNF<sup>&#x2b;</sup>, <bold>(b)</bold> IFN&#x3b3;<sup>&#x2b;</sup>, and <bold>(c)</bold> granzyme B (GrzB)<sup>&#x2b;</sup> cells within N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. The expression of TNF and IFN&#x3b3; was assessed after stimulation with PMA, Ionomycin and BFA (PMA/Iono) for 4&#xa0;h and anti-CD3 and BFA (CD3) for 16&#xa0;h while GrzB levels were measured in unstimulated cells. n &#x3d; 25 in each subset. Friedman test, Dunn&#x2019;s post hoc test. &#x2a;p &#x3c; 0.05; &#x2a;&#x2a;p &#x3c; 0.01; &#x2a;&#x2a;&#x2a;p &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;p &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g002.tif">
<alt-text content-type="machine-generated">Scatter plots show the percentage of CD8 T cell subsets positive for TNF and IFN&#x3B3; with PMA/Ionomycin or &#x3B1;-CD3 stimulation, and GrzB positive cells. Significant differences indicated by asterisks (P&#x3C;0.05 to P&#x3C;0.0001) among subsets: NCCR7, NCD28, NCD27, and NTN. Plots display data variability with error bars.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-2">
<title>Mitochondria, ROS, and senescence in na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets</title>
<p>We next measured the expression of parameters related to mitochondrial functionality, oxidative stress, and senescence in N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells (<xref ref-type="fig" rid="F3">Figure 3</xref>). Total mitochondrial content, assessed using mitotracker DR, was highest in N<sub>CD28</sub> and progressively decreased in N<sub>CCR7</sub>, N<sub>CD27</sub> and N<sub>TN</sub> subsets (<xref ref-type="fig" rid="F3">Figure 3a</xref>). Mitochondrial membrane potential, a key indicator of mitochondrial health and activity, was evaluated using JC-1 intensity, normalised on mitochondrial content. While N<sub>CD28</sub> cells exhibited the lowest JC-1 intensity, it was progressively higher in the N<sub>CCR7</sub>, N<sub>CD27</sub> and N<sub>TN</sub> subsets (<xref ref-type="fig" rid="F3">Figure 3b</xref>). The highest JC-1 values were found in N<sub>TN</sub> cells. Both mitochondrial and intracellular ROS were elevated in N<sub>CD27</sub> cells, intermediate in N<sub>CCR7</sub> and N<sub>CD28</sub>, and lowest in the N<sub>TN</sub> population (<xref ref-type="fig" rid="F3">Figures 3c,d</xref>). Similarly, SA-&#x3b2;-gal activity was higher in the N<sub>CCR7</sub>, decreased in N<sub>CD28</sub> and N<sub>CD27</sub> and significantly lower in N<sub>TN</sub> cells (<xref ref-type="fig" rid="F3">Figure 3d</xref>). Elevated SA-&#x3b2;-gal activity was present in T<sub>SCM</sub> cells (<xref ref-type="sec" rid="s12">Supplementary Figure S3g</xref>). In parallel, the senescence marker p21 was expressed at comparable levels in the N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> subpopulations, but it was reduced in the N<sub>TN</sub> subset (<xref ref-type="fig" rid="F3">Figure 3e</xref>). In summary, the four na&#xef;ve subsets are unique regarding the functionality of mitochondria and markers of oxidative stress and senescence.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Mitochondria, ROS, and senescence markers in na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets. <bold>(a)</bold> MitoTracker deep red (DR) mean fluorescence intensity (MFI), <bold>(b)</bold> JC-1 normalized ratio (JC-1 green/red MFI normalized against MitoTracker DR MFI), <bold>(c)</bold> MitoTracker Red CMXRos (MitROS) MFI, <bold>(d)</bold> DHE MFI, <bold>(e)</bold> frequency of SA-&#x3b2;-gal<sup>&#x2b;</sup> cells, and <bold>(f)</bold> p21 MFI within N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. n &#x3d; 31 (MitoTracker DR, JC-1, MitROS), n &#x3d; 48 (DHE, SA-&#x3b2;-gal) n &#x3d; 26 (p21) in each subset. Friedman test, Dunn&#x2019;s post hoc test. &#x2a;p &#x3c; 0.05; &#x2a;&#x2a;p &#x3c; 0.01; &#x2a;&#x2a;&#x2a;p &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;p &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g003.tif">
<alt-text content-type="machine-generated">Graphical data displays six scatter plots labeled a to f, each comparing various measurements within CD8 T cell subsets marked as \(N_{\text{CCR7}}\), \(N_{\text{CD28}}\), \(N_{\text{CD27}}\), and \(N_{\text{TN}}\). Each plot shows individual data points with mean values, and significant differences are marked by asterisks. The plots measure Mitotracker DR, JC-1, MitROS, ROS, SA-&#x3B2;-gal, and p21.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-3">
<title>Apoptosis and proliferation in N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells</title>
<p>We next assessed whether naive CD8<sup>&#x2b;</sup> T cells may respond differently to DNA damage (<xref ref-type="fig" rid="F4">Figure 4</xref>). To achieve this aim, PBMCs were stimulated for 1&#xa0;day with etoposide, and markers of apoptosis were assessed within N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells (<xref ref-type="fig" rid="F4">Figure 4</xref>). We first measured the frequency of early and late apoptotic cells using the combination of Apotracker and DAPI, and therefore Apotracker (Apo)<sup>&#x2b;</sup> DAPI<sup>&#x2212;</sup> and Apo<sup>&#x2b;</sup> DAPI<sup>&#x2b;</sup> populations were defined (<xref ref-type="fig" rid="F4">Figure 4a</xref>). The frequency of both early and late apoptotic cells was the highest in N<sub>CCR7</sub>, intermediate in N<sub>CD28</sub> and N<sub>CD27</sub> and the lowest in N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells, indicating that N<sub>TN</sub> may be more resistant to DNA damage-induced apoptosis. Similarly, the levels of cleaved caspase 3 decreased in N<sub>TN</sub> cells, although no statistically significant differences were found between N<sub>CCR7</sub>, N<sub>CD28</sub>, and N<sub>CD27</sub> cells (<xref ref-type="fig" rid="F4">Figure 4b</xref>). &#x3b3;H2AX levels, indicating the presence of DNA double-strand breaks (<xref ref-type="bibr" rid="B22">Podhorecka et al., 2010</xref>), were measured in the four subsets, and N<sub>CCR7</sub> and N<sub>TN</sub> cells showed the highest and the lowest &#x3b3;H2AX levels respectively. We next measured proliferation of the subpopulations of interest within PBMCs after stimulation with anti-CD3 Ab or PHA for 4&#xa0;days (<xref ref-type="fig" rid="F5">Figure 5</xref>). Both PI and frequency of proliferated cells were again the lowest in N<sub>CCR7</sub>, intermediate in the N<sub>CD28</sub> and N<sub>CD27</sub> subsets, while N<sub>TN</sub> showed the highest proliferation rate in comparison to the other populations. Results were similar for the stimulation with anti-CD3 and PHA.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Apoptosis and DNA damage in na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets. <bold>(a)</bold> Frequency of early apoptotic Apotracker<sup>&#x2b;</sup>DAPI<sup>&#x2212;</sup> (Apo<sup>&#x2b;</sup>DAPI<sup>&#x2212;</sup>), and late apoptotic Apotracker<sup>&#x2b;</sup>DAPI<sup>&#x2b;</sup> (Apo<sup>&#x2b;</sup>DAPI<sup>&#x2b;</sup>) cells within N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. Representative FACS plots displaying high (N<sub>CCR7</sub>) and low (N<sub>TN</sub>) apoptosis levels are shown. Frequency of <bold>(b)</bold> caspase 3<sup>&#x2b;</sup> and <bold>(c)</bold> &#x3b3;H2AX<sup>&#x2b;</sup> cells within na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets. n &#x3d; 29 in each subset. Friedman test, Dunn&#x2019;s post hoc test. &#x2a;p &#x3c; 0.05; &#x2a;&#x2a;p &#x3c; 0.01; &#x2a;&#x2a;&#x2a;p &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;p &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g004.tif">
<alt-text content-type="machine-generated">Graphs and scatter plots showing cell apoptosis and related markers. Bar graphs (a) show early and late apoptotic percentages in CD8+ T cell subsets with significant differences marked. Scatter plots show apoptotic cell distributions in N\(_{CCR7}\) and N\(_{TN}\). Bar graph (b) presents Caspase 3 levels, and (c) shows H2AX levels, both indicating significant group differences.</alt-text>
</graphic>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Proliferation potential of N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. Proliferation potential of CD8<sup>&#x2b;</sup> na&#xef;ve T cell subsets after stimulation with <bold>(a)</bold> PHA and <bold>(b)</bold> anti-CD3 Ab for 4 days. Proliferation was displayed using the proliferation index (PI) and the frequency of proliferated cells. Representative histograms showing CPD450 intensity in the N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> subsets in stimulated and unstimulated cells are shown. n &#x3d; 25 in each subset. Friedman test, Dunn&#x2019;s post hoc test. &#x2a;p &#x3c; 0.05; &#x2a;&#x2a;p &#x3c; 0.01; &#x2a;&#x2a;&#x2a;p &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;p &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g005.tif">
<alt-text content-type="machine-generated">Charts and histograms show proliferation indices (PI) and percentage of proliferated cells in CD8 T cells, grouped by subsets: NCCR7, NCD28, NCD27, NTN. Significant results are marked by asterisks, demonstrating differences in PI and cell proliferation both with PHA (a) and CD3 stimulation (b). Histograms on the right depict CPD450 intensity, comparing unstimulated and various subsets with distinct color coding.</alt-text>
</graphic>
</fig>
<p>Taken together, although the response to DNA damage and proliferative capacities differ across the subsets, the N<sub>CD27</sub> subset appears most closely related to N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells.</p>
</sec>
<sec id="s3-4">
<title>Distinct immunological profiles can be defined by differential marker expression in N<sub>CCR7</sub>-N<sub>CD28</sub> and N<sub>CD27</sub>-N<sub>TN</sub> cell populations</title>
<p>We then used an unsupervised hierarchical clustering approach to delineate discrete patterns of markers across the entire dataset including the data shown in <xref ref-type="fig" rid="F1">Figures 1</xref>&#x2013;<xref ref-type="fig" rid="F4">4</xref> (<xref ref-type="fig" rid="F6">Figure 6a</xref>). In this way, we identified two theoretical clusters of cells (<xref ref-type="fig" rid="F6">Figures 6a,b</xref>). By analysing the relative weight of each marker onto the clustering model, we observed that cluster one showed significantly lower expression of the differentiation markers CX3CR1, CD16, CD56 and NKp80, as well as decreased TNF, IFN&#x3b3;, SA-&#xdf;-gal, and apoptosis. Conversely, cluster two showed an increased level of the same markers. Interestingly, significant differences were additionally driven by apoptosis markers (<xref ref-type="fig" rid="F6">Figure 6a</xref>). Next, cells from the four original subpopulations were identified within the theoretical groups obtained using the clustering algorithm (<xref ref-type="fig" rid="F6">Figure 6c</xref>). Our data show that N<sub>CD27</sub> and N<sub>TN</sub> were mostly assigned to cluster 1, whereas N<sub>CCR7</sub> and N<sub>CD28</sub> were almost exclusively represented within cluster 2 (<xref ref-type="fig" rid="F6">Figure 6c</xref>). This data was confirmed using the correspondence analysis, showing N<sub>CD27</sub> and N<sub>TN</sub> and cluster one in the opposite quadrant as N<sub>CCR7</sub> and N<sub>CCR8</sub> and cluster 2 (<xref ref-type="fig" rid="F6">Figure 6d</xref>). Altogether these findings show a remarkable similarity in the phenotype of N<sub>CD27</sub> and N<sub>TN</sub>, as well as a similar scenario for N<sub>CCR7</sub> and N<sub>CD28</sub> subpopulations.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Unsupervised clustering of N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. <bold>(a)</bold> Hierarchical clustering showing two predominant patterns of expression of immunological parameter. Parameters are arranged vertically according to their discriminative impact on the clustering algorithm. Scatter plot was used to determine the ideal number of clusters to select within the dataset. A model with n &#x3d; 2 clusters provides the biggest reduction in the distance from centroids. <bold>(b)</bold> Scatter plot allowing the visualization of cluster separation. <bold>(c)</bold> Frequency distribution of cell subpopulations within the theoretical subpopulations identified using unsupervised clustering. Fisher&#x2019;s exact test p &#x3c; 0.0001. <bold>(d)</bold> Multiple correspondence analysis confirming the association between N<sub>CC27</sub> and N<sub>TN</sub> with cluster one and N<sub>CCR7</sub> and N<sub>CD28</sub> with cluster 2.</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g006.tif">
<alt-text content-type="machine-generated">Cluster analysis image with heatmap, PCA plot, and bar graph. (a) Heatmap displaying two clusters (Cluster 1 and Cluster 2) with varying expression levels of markers such as CD16 and CD94, indicated by blue to red color gradients. A dendrogram shows hierarchical clustering, with a line graph indicating two optimal clusters.(b) PCA plot showing two distinct clusters (Cluster 1 in purple, Cluster 2 in green) with overlapping data points for N_CD27, N_TN, N_CCR7, and N_CD28.(c) Bar graph depicting the percentage distribution of subjects across two clusters for different markers.(d) Dimensional reduction plot with clusters and markers denoted by distinct colors.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-5">
<title>The effect of age on N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells</title>
<p>We next investigated whether the expression of all markers measured in the four naive CD8<sup>&#x2b;</sup> T cells may change with aging (<xref ref-type="fig" rid="F7">Figures 7</xref>, <xref ref-type="fig" rid="F8">8</xref>; <xref ref-type="sec" rid="s12">Supplementary Figure S4</xref>). Overall, the expression of differentiation markers and pro-inflammatory/effector molecules increased with age within all subsets, although most significant results were seen for N<sub>CD28</sub> and N<sub>CD27</sub> cells (<xref ref-type="fig" rid="F7">Figure 7</xref>). Furthermore, mitochondrial membrane potential was reduced in all subpopulations with age while ROS levels increased. Importantly, in all subsets, highly significant correlations were observed between SA-&#xdf;-gal expression and age. Furthermore, the proliferation potential decreased with aging, with the most prominent differences observed for N<sub>CCR7</sub>, N<sub>CD28</sub>, and N<sub>CD27</sub> cells. Finally, reduced apoptosis was described, although no correlations between &#x3b3;H2AX levels and aging were identified. We next divided the donors into three age groups: young (&#x2264;35 years), middle-aged (36&#x2013;69&#xa0;years) and old (&#x2265;70&#xa0;years) and investigated the expression of CX3CR1, CD94, Tbet, intracellular ROS levels and SA-&#xdf;-gal in N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cell subsets (<xref ref-type="fig" rid="F8">Figure 8</xref>). The most significant differences were observed between the young and old groups within the N<sub>CCR7</sub>, N<sub>CD28</sub> and N<sub>CD27</sub> subsets, while the middle-aged donors generally resembled the younger group. Although certain trends were present, no significant differences were detected in the N<sub>TN</sub> subset.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Correlation analysis against age. Correlation of each parameter considered in the study (<xref ref-type="fig" rid="F1">Figures 1</xref>&#x2013;<xref ref-type="fig" rid="F5">5</xref>) against age. Spearman correlation coefficient (r<sub>S</sub>), p values, and n are shown. For positive correlations, significant p values are displayed using a blue gradient (p &#x3d; 0.05 light blue, p &#x3c; 0.0001 dark blue), while for negative correlations p values are shown in red (p &#x3d; 0.05 light red, p &#x3c; 0.0001 dark red).</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g007.tif">
<alt-text content-type="machine-generated">Correlation matrix displaying data for different proteins and markers across five categories (N_CCR7, N_28, N_27, N_TN, N). Each category has correlation coefficients (r_s) with corresponding p-values. A color gradient indicates the strength and direction of correlations, with blue for positive correlations and red for negative. Right side features a color legend.</alt-text>
</graphic>
</fig>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>The effect of age on N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. Expression of <bold>(a)</bold> CX3CR1, <bold>(b)</bold> CD94, mean fluorescence intensity (MFI) of Tbet <bold>(c)</bold> intracellular ROS (&#x3d;DHE MFI, <bold>(d)</bold>, and <bold>(e)</bold> SA-&#x3b2;-gal<sup>&#x2b;</sup> cells in N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells of young (&#x2264;35 years), middle-aged (36&#x2013;69 years), and old (&#x2265;70 years) donors. Friedman test, Dunn&#x2019;s post hoc test. &#x2a;p &#x3c; 0.05; &#x2a;&#x2a;p &#x3c; 0.01; &#x2a;&#x2a;&#x2a;p &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;p &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g008.tif">
<alt-text content-type="machine-generated">Five graphs depict data related to CD8&#x207A; T cell subsets in young, middle-aged, and old individuals. The graphs show percentages and measurements for CX3CR1, CD94, Tbet, ROS intra, and SA-&#x3B2;-gal markers across different subsets (N_CCR7, N_2B, N_2T, N_TN). Significant differences are marked by asterisks, indicating statistical relevance.</alt-text>
</graphic>
</fig>
<p>In summary, impaired phenotype and functionality (including the acquisition of an activated phenotype and loss of quiescence) were observed during aging in naive CD8<sup>&#x2b;</sup> T cells. Although less pronounced, some age-related changes were also identified in the N<sub>TN</sub> subset.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>CD8<sup>&#x2b;</sup> T cells play a key role within the adaptive immune system, enabling the recognition and elimination of intracellular pathogens as well as cancer cells (<xref ref-type="bibr" rid="B1">Appay et al., 2008</xref>). After exposure to antigens, na&#xef;ve CD8<sup>&#x2b;</sup> T cells are activated and differentiate into diverse populations of effector/memory CD8<sup>&#x2b;</sup> T cells. Complete activation of na&#xef;ve CD8<sup>&#x2b;</sup> T cells requires the expression of costimulatory receptors, including CD28 and CD27, which provide survival and proliferation cues (<xref ref-type="bibr" rid="B7">Dolfi and Katsikis, 2007</xref>). Evidence exists that the na&#xef;ve CD8<sup>&#x2b;</sup> T cell pool may be highly heterogeneous regarding phenotype and differentiation status, influenced by factors including thymic function and age (<xref ref-type="bibr" rid="B32">van den Broek et al., 2018</xref>). Furthermore, while several studies present in the literature have characterized the phenotype and the functionality of na&#xef;ve T cells, this subset has been defined in various ways, making proper interpretation of results challenging.</p>
<p>One of the aims of this study was to compare the phenotype of na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets defined using four different combinations of markers, all expressing the CD45 isoform CD45RA. We considered subpopulations expressing the lymph node homing receptor CCR7 (CD45RA<sup>&#x2b;</sup>CCR7<sup>&#x2b;</sup>, N<sub>CCR7</sub>), CD28 (CD45RA<sup>&#x2b;</sup>CD28<sup>&#x2b;</sup>, N<sub>CD28</sub>), CD27 (CD45RA<sup>&#x2b;</sup>CD27<sup>&#x2b;</sup>, N<sub>CD27</sub>), and cells positive for all markers but lacking the terminally differentiation molecule CD57 (CD45RA<sup>&#x2b;</sup>CCR7<sup>&#x2b;</sup>CD28<sup>&#x2b;</sup>CD27<sup>&#x2b;</sup>CD57<sup>&#x2212;</sup>, N<sub>TN</sub>). Although N<sub>CCR,</sub> N<sub>CD28,</sub> and N<sub>CD27</sub> have been partially characterized in other studies (<xref ref-type="bibr" rid="B15">Larbi and Fulop, 2014</xref>; <xref ref-type="bibr" rid="B31">van Aalderen et al., 2021</xref>), it remains unclear which of these subpopulations exhibit the typical phenotype of <italic>bona fide</italic> na&#xef;ve CD8<sup>&#x2b;</sup> T cells and whether they are phenotypically similar. We therefore analysed the expression of differentiation markers, cytokines, effector molecules, and functional characteristics of the four na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets within PBMCs from healthy donors of different age. As expected from previous studies (<xref ref-type="bibr" rid="B13">Koch et al., 2008</xref>), N<sub>TN</sub> cells displayed characteristics most closely aligned with na&#xef;ve cells, as they exhibited very low expression of differentiation markers, pro-inflammatory cytokines and effector molecules, along with excellent mitochondrial fitness, low levels of ROS and senescence markers, reduced DNA damage-induced apoptosis and high proliferation potential after stimulation. Despite this, notable differences among the na&#xef;ve subsets were observed across all parameters considered. Our analysis of mitochondrial parameters revealed interesting differences among the subsets. N<sub>CD28</sub> cells showed the highest mitochondrial content but the lowest membrane potential, suggesting unique mechanisms of mitophagy or mitochondrial biogenesis. N<sub>CCR7</sub>, N<sub>CD27</sub>, and N<sub>TN</sub> cells displayed higher membrane potential, with N<sub>TN</sub> cells exhibiting the highest values. Importantly, mitochondrial parameters were different between the N<sub>CD27</sub> and N<sub>TN</sub> subsets. These findings align with recent studies highlighting the importance of mitochondrial function in T cell differentiation and function (<xref ref-type="bibr" rid="B25">Steinert et al., 2021</xref>). Senescence markers (SA-&#x3b2;-gal and p21) showed variable expression across the subsets, with N<sub>TN</sub> cells consistently showing the lowest levels. This suggests that N<sub>TN</sub> cells may be less prone to senescence compared to the other subsets. Apoptosis assays suggest that N<sub>TN</sub> cells may be more resistant to DNA damage-induced apoptosis, which could contribute to their persistence in the na&#xef;ve T cell pool. Furthermore, N<sub>TN</sub> cells showed the highest proliferation rate upon stimulation, therefore suggesting that this subset may be most potent to mount immune responses after antigenic contact, therefore being important in responding to infections and vaccinations. To further explore the functional distinctiveness of na&#xef;ve subsets, we compared the expression of markers associated with activation, senescence, and cytotoxicity between T<sub>SCM</sub> cells and the other four na&#xef;ve T cell subsets. Our analysis revealed that the T<sub>SCM</sub> subset differ markedly from the other subpopulations, frequently exhibiting phenotypic traits characteristic of more differentiated T cells (<xref ref-type="bibr" rid="B30">Tomiyama et al., 2004</xref>). These results are consistent with previous studies (<xref ref-type="bibr" rid="B34">Zou et al., 2025</xref>; <xref ref-type="bibr" rid="B16">Muroyama and Wherry, 2021</xref>) and support the notion that T<sub>SCM</sub> represent a memory T cell population, clearly distinguishable from na&#xef;ve T cells both phenotypically and functionally.</p>
<p>Intriguingly, unsupervised hierarchical clustering identified two distinct clusters: cluster one exclusively including the N<sub>CD27</sub> and N<sub>TN</sub> subset, and cluster two predominantly represented by N<sub>CCR7</sub> and N<sub>CD28</sub> cells. Importantly, while the levels of differentiation markers, pro-inflammatory cytokines, senescence molecules, and DNA damage-induced apoptosis were particularly low in cluster 1, they were found to be increased within cluster 2. Moreover, the expression of most molecules was highly heterogeneous in the N<sub>CCR7</sub> and N<sub>CD28</sub> subsets while being more homogeneous in N<sub>CD27</sub> and N<sub>TN</sub> cells. This was particularly evident when assessing the levels of differentiation markers. Thus, these results suggest that N<sub>CCR7</sub> and N<sub>CD28</sub> cells likely include other &#x201c;non-na&#xef;ve&#x201d; cell types. Indeed, a small percentage of CD28<sup>&#x2212;</sup>CD45RA<sup>&#x2b;</sup> cells was found within the N<sub>CCR7</sub> and N<sub>CD27</sub> subsets while some CD27<sup>&#x2212;</sup>CD45RA<sup>&#x2b;</sup> cells were present within the N<sub>CCR7</sub> and N<sub>CD28</sub> subpopulations (<xref ref-type="sec" rid="s12">Supplementary Figure S5</xref>). A schematic illustration showing the conceptual relationship among the four na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets is shown in <xref ref-type="fig" rid="F9">Figure 9</xref>.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Schematic illustration of the relationship between N<sub>CCR7</sub>, N<sub>CD28</sub>, N<sub>CD27</sub> and N<sub>TN</sub> CD8<sup>&#x2b;</sup> T cells. Nested diagram showing the conceptual relationship among the four na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets.</p>
</caption>
<graphic xlink:href="fragi-07-1765665-g009.tif">
<alt-text content-type="machine-generated">Concentric circles in shades of green, labeled from the outermost to innermost: \(N_{\text{CCR7}}\), \(N_{\text{CD28}}\), \(N_{\text{CD27}}\), and \(N_{\text{TN}}\). Each smaller circle is nested within the larger one.</alt-text>
</graphic>
</fig>
<p>In addition, this heterogeneity may arise from age-related differences in the expression of the parameters of interest. Aging negatively affects the efficacy of immune responses, leading to increased severity of infectious diseases and impaired responses to vaccinations in the elderly (<xref ref-type="bibr" rid="B5">Crooke et al., 2019</xref>). Aging significantly impacts na&#xef;ve T cells, as thymic involution represents one of the earliest and most prominent changes associated with immunosenescence (<xref ref-type="bibr" rid="B11">George and Ritter, 1996</xref>). Despite this decline in thymic output, the na&#xef;ve T cell pool is maintained during aging through homeostatic proliferation mechanisms of existing T cells (<xref ref-type="bibr" rid="B33">Weyand and Goronzy, 2016</xref>). A typical aspect intrinsically connected to aging is inflammaging, chronic, sterile, low-grade inflammation developing with aging itself and known to contribute to age-related diseases (<xref ref-type="bibr" rid="B9">Franceschi et al., 2018</xref>; <xref ref-type="bibr" rid="B27">Teissier et al., 2022</xref>). This persistent pro-inflammatory condition is closely linked to cellular senescence, as senescent cells secrete pro-inflammatory molecules as part of their senescence-associated secretory phenotype (SASP (<xref ref-type="bibr" rid="B3">Copp&#xe9; et al., 2010</xref>)). Importantly, inflammaging alters immune functionality, additionally affecting na&#xef;ve T cell activation (<xref ref-type="bibr" rid="B24">Shchukina et al., 2023</xref>). In particular, a vicious cycle of inflammation may be induced, in which some na&#xef;ve T cells may be activated by SASP factors and therefore contribute to inflammaging itself with the secretion of pro-inflammatory molecules. Inflammaging directly affects na&#xef;ve T cell activation, as the pro-inflammatory molecules TNF, IL-6 and IL-1 lead to na&#xef;ve T cell activation and differentiation (<xref ref-type="bibr" rid="B6">Curtsinger et al., 1999</xref>). In addition, altered function of dendritic cells induced by inflammaging itself, as well as impaired formation of the immunological synapse (<xref ref-type="bibr" rid="B26">Tai et al., 2018</xref>), further support na&#xef;ve T cell dysfunction. Consequently, due to inflammaging effects, this subset may show reduced proliferation, increased differentiation towards effector phenotypes, impaired homeostasis and increased susceptibility to exhaustion and senescence (<xref ref-type="bibr" rid="B24">Shchukina et al., 2023</xref>). In line with these observations, we documented an overall increase in the expression of differentiation markers, molecules related to inflammation, oxidative stress, and senescence, as well as decreased proliferation and DNA damage-induced apoptosis, in all na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets during aging. Although stronger correlations were observed in the N<sub>CCR7</sub> and N<sub>CD28</sub> subsets, age-related changes were also present in N<sub>CD27</sub> and N<sub>TN</sub> cells.</p>
<p>In conclusion, our study reveals a previously unappreciated heterogeneity within the na&#xef;ve CD8<sup>&#x2b;</sup> T cell compartment, with implications for our understanding of T cell differentiation, aging, and immune responses. The N<sub>TN</sub> phenotype, while still subject to age-related alterations, may provide a more precise definition of na&#xef;ve T cells compared to the other combinations of markers. In instances where this most optimal definition of na&#xef;ve CD8<sup>&#x2b;</sup> T cells cannot be applied, the combined expression of CD45RA and CD27 may be considered an appropriate alternative. Future studies should assess the phenotype of na&#xef;ve T cell subsets in pathological conditions. In addition, the functional implications of these subset differences need to be assessed <italic>in vivo</italic>, particularly in the context of aging and immune responses to novel antigens. Additionally, exploring the epigenetic landscape of these subsets could provide insights into the mechanisms underlying their distinct phenotypes and functional characteristics.</p>
<sec id="s4-1">
<title>Data limitations and perspectives</title>
<p>Although a small proportion (&#x223c;10%) of CX3CR1<sup>&#x2b;</sup>, CD16<sup>&#x2b;</sup>, or NKp80<sup>&#x2b;</sup> cells was detected within the N<sub>CCR7</sub> and N<sub>CD28</sub> subsets, this observation requires further investigation. While our experimental data support the presence of these cells, additional validation is needed to determine whether this reflects a true biological phenomenon or subtle technical limitations related to donor variability or gating parameters. Furthermore, the lack of alternative gating strategies to define na&#xef;ve T cells (such as CCR7/Fas-based approaches) represents a limitation of the current study.</p>
<p>This study relies primarily on phenotypic analyses using well-established surface markers to define na&#xef;ve CD8<sup>&#x2b;</sup> T cell subsets. Despite comprehensive characterization, these markers may not fully capture the underlying heterogeneity or functional diversity within the na&#xef;ve compartment. Moreover, potential contamination with partially differentiated or non-na&#xef;ve cells in some subsets highlights the limitation of surface marker-based definitions. While our hierarchical clustering provided additional resolution, deeper insights could be obtained through high-dimensional approaches such as single-cell RNA sequencing or epigenetic profiling, which were beyond the scope of this study.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s12">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="s6">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Ethics Committee of the Medical University of Innsbruck, protocol n 1204/2024 and 1358/2021. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>LP: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualisation, Writing &#x2013; original draft, Writing &#x2013; review and editing. PP: Writing &#x2013; review and editing, Writing &#x2013; original draft, Investigation, Data curation. LH: Writing &#x2013; review and editing, Investigation, Writing &#x2013; original draft, Formal Analysis. MB: Writing &#x2013; review and editing, Data curation, Writing &#x2013; original draft, Investigation. GC: Writing &#x2013; original draft, Writing &#x2013; review and editing, Formal Analysis, Methodology, Data curation. MK: Writing &#x2013; review and editing, Writing &#x2013; original draft, Investigation. BJ: Conceptualization, Writing &#x2013; review and editing, Investigation, Writing &#x2013; original draft. MC: Conceptualization, Writing &#x2013; review and editing, Writing &#x2013; original draft, Methodology. BW: Resources, Writing &#x2013; review and editing, Writing &#x2013; original draft, Conceptualization, Funding acquisition, Supervision.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors thank the University of Innsbruck (Austria) for providing financial support for this study.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s10">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s12">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fragi.2026.1765665/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fragi.2026.1765665/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Presentation2.pptx" id="SM1" mimetype="application/pptx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2106487/overview">Keon-Il Im</ext-link>, The Catholic University of Korea, Republic of Korea</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1131475/overview">Cangang Zhang</ext-link>, Xi&#x2019;an Jiaotong University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3317902/overview">Saseong Lee</ext-link>, Department of Comparative Medicine, United States</p>
</fn>
</fn-group>
<fn-group>
<fn fn-type="abbr" id="abbrev1">
<label>Abbreviations:</label>
<p>Ab, antibody; BFA, Brefeldin A; CPD450, Cell Proliferation Dye eFluor&#x2122; 450; DHE, Dihydroethidium; PHA, Phytohemagglutinin; PI, proliferation index; SA-&#x3b2;-gal, senescence-associated &#x3b2;-galactosidase.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appay</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Douek</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>CD8&#x2b; T cell efficacy in vaccination and disease</article-title>. <source>Nat. Med.</source> <volume>14</volume> (<issue>6</issue>), <fpage>623</fpage>&#x2013;<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1038/nm.f.1774</pub-id>
<pub-id pub-id-type="pmid">18535580</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appay</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fastenackels</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Katlama</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ait-Mohand</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guihot</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients</article-title>. <source>AIDS</source> <volume>25</volume> (<issue>15</issue>), <fpage>1813</fpage>&#x2013;<lpage>1822</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32834640e6</pub-id>
<pub-id pub-id-type="pmid">21412126</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Copp&#xe9;</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Desprez</surname>
<given-names>P. Y.</given-names>
</name>
<name>
<surname>Krtolica</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Campisi</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The senescence-associated secretory phenotype: the dark side of tumor suppression</article-title>. <source>Annu. Rev. Pathol.</source> <volume>5</volume>, <fpage>99</fpage>&#x2013;<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-121808-102144</pub-id>
<pub-id pub-id-type="pmid">20078217</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossarizza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Radbruch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abrignani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Addo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Akdis</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)</article-title>. <source>Eur. J. Immunol.</source> <volume>51</volume> (<issue>12</issue>), <fpage>2708</fpage>&#x2013;<lpage>3145</lpage>. <pub-id pub-id-type="doi">10.1002/eji.202170126</pub-id>
<pub-id pub-id-type="pmid">34910301</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crooke</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Ovsyannikova</surname>
<given-names>I. G.</given-names>
</name>
<name>
<surname>Poland</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>R. B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Immunosenescence and human vaccine immune responses</article-title>. <source>Immun. Ageing</source> <volume>16</volume>, <fpage>25</fpage>. <pub-id pub-id-type="doi">10.1186/s12979-019-0164-9</pub-id>
<pub-id pub-id-type="pmid">31528180</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curtsinger</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Mondino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lins</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Kedl</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>M. K.</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>). <article-title>Inflammatory cytokines provide a third signal for activation of naive CD4&#x2b; and CD8&#x2b; T cells</article-title>. <source>J. Immunol.</source> <volume>162</volume> (<issue>6</issue>), <fpage>3256</fpage>&#x2013;<lpage>3262</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.162.6.3256</pub-id>
<pub-id pub-id-type="pmid">10092777</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolfi</surname>
<given-names>D. V.</given-names>
</name>
<name>
<surname>Katsikis</surname>
<given-names>P. D.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>CD28 and CD27 costimulation of CD8&#x2b; T cells: a story of survival</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>590</volume>, <fpage>149</fpage>&#x2013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-34814-8_11</pub-id>
<pub-id pub-id-type="pmid">17191384</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egorov</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Kasatskaya</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Zubov</surname>
<given-names>V. N.</given-names>
</name>
<name>
<surname>Izraelson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nakonechnaya</surname>
<given-names>T. O.</given-names>
</name>
<name>
<surname>Staroverov</surname>
<given-names>D. B.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>The changing landscape of naive T cell receptor repertoire with human aging</article-title>. <source>Front. Immunol.</source> <volume>9</volume>, <fpage>1618</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01618</pub-id>
<pub-id pub-id-type="pmid">30087674</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franceschi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garagnani</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Parini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Giuliani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Santoro</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Inflammaging: a new immune-metabolic viewpoint for age-related diseases</article-title>. <source>Nat. Rev. Endocrinol.</source> <volume>14</volume> (<issue>10</issue>), <fpage>576</fpage>&#x2013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1038/s41574-018-0059-4</pub-id>
<pub-id pub-id-type="pmid">30046148</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geginat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lanzavecchia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sallusto</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Proliferation and differentiation potential of human CD8&#x2b; memory T-cell subsets in response to antigen or homeostatic cytokines</article-title>. <source>Blood</source> <volume>101</volume> (<issue>11</issue>), <fpage>4260</fpage>&#x2013;<lpage>4266</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2002-11-3577</pub-id>
<pub-id pub-id-type="pmid">12576317</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Ritter</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Thymic involution with ageing: obsolescence or good housekeeping?</article-title> <source>Immunol. Today</source> <volume>17</volume> (<issue>6</issue>), <fpage>267</fpage>&#x2013;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1016/0167-5699(96)80543-3</pub-id>
<pub-id pub-id-type="pmid">8962629</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamimura</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Atsumi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stofkova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ohki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Na&#xef;ve T cell homeostasis regulated by stress responses and TCR signaling</article-title>. <source>Front. Immunol.</source> <volume>6</volume>, <fpage>638</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2015.00638</pub-id>
<pub-id pub-id-type="pmid">26734005</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Larbi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Derhovanessian</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ozcelik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Naumova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pawelec</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people</article-title>. <source>Immun. Ageing</source> <volume>5</volume>, <fpage>6</fpage>. <pub-id pub-id-type="doi">10.1186/1742-4933-5-6</pub-id>
<pub-id pub-id-type="pmid">18657274</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koh</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. U.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>E. C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Human CD8&#x2b; T-Cell populations that express natural killer receptors</article-title>. <source>Immune Netw.</source> <volume>23</volume> (<issue>1</issue>), <fpage>e8</fpage>. <pub-id pub-id-type="doi">10.4110/in.2023.23.e8</pub-id>
<pub-id pub-id-type="pmid">36911797</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larbi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fulop</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>From truly na&#xef;ve to exhausted senescent T cells: when markers predict functionality</article-title>. <source>Cytom. A</source> <volume>85</volume> (<issue>1</issue>), <fpage>25</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.a.22351</pub-id>
<pub-id pub-id-type="pmid">24124072</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muroyama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wherry</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Memory T-Cell heterogeneity and terminology</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>13</volume> (<issue>10</issue>), <fpage>a037929</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a037929</pub-id>
<pub-id pub-id-type="pmid">33782027</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangrazzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>T cells, aging and senescence</article-title>. <source>Exp. Gerontol.</source> <volume>134</volume>, <fpage>110887</fpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2020.110887</pub-id>
<pub-id pub-id-type="pmid">32092501</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangrazzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meryk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Naismith</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Koziel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lair</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Krismer</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017a</year>). <article-title>Inflamm-aging influences immune cell survival factors in human bone marrow</article-title>. <source>Eur. J. Immunol.</source> <volume>47</volume> (<issue>3</issue>), <fpage>481</fpage>&#x2013;<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201646570</pub-id>
<pub-id pub-id-type="pmid">27995612</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangrazzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Naismith</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Meryk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jenewein</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Trieb</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2017b</year>). <article-title>Increased IL-15 production and accumulation of highly differentiated CD8&#x2b; effector/memory T cells in the bone marrow of persons with Cytomegalovirus</article-title>. <source>Front. Immunol.</source> <volume>8</volume>, <fpage>715</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00715</pub-id>
<pub-id pub-id-type="pmid">28674537</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangrazzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Reidla</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carmona Arana</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Naismith</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Miggitsch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meryk</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>CD28 and CD57 define four populations with distinct phenotypic properties within human CD8&#x2b; T cells</article-title>. <source>Eur. J. Immunol.</source> <volume>50</volume> (<issue>3</issue>), <fpage>363</fpage>&#x2013;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201948362</pub-id>
<pub-id pub-id-type="pmid">31755098</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pangrazzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Martic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cavinato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Detecting senescence in T cells by flow cytometry using the SA-&#x3b2;-Galactosidase assay</article-title>. <source>Methods Mol. Biol.</source> <volume>2906</volume>, <fpage>73</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-4426-3_5</pub-id>
<pub-id pub-id-type="pmid">40082351</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Podhorecka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Skladanowski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bozko</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>H2AX phosphorylation: its role in DNA damage response and cancer therapy</article-title>. <source>J. Nucleic Acids</source> <volume>3</volume>, <fpage>920161</fpage>. <pub-id pub-id-type="doi">10.4061/2010/920161</pub-id>
<pub-id pub-id-type="pmid">20811597</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seshadri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vivek</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prizment</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Crimmins</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Klopack</surname>
<given-names>E. T.</given-names>
</name>
<name>
<surname>Faul</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Immune cells are associated with mortality: the Health and Retirement Study</article-title>. <source>Front. Immunol.</source> <volume>14</volume>, <fpage>1280144</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1280144</pub-id>
<pub-id pub-id-type="pmid">37928548</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shchukina</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bohacova</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Artyomov</surname>
<given-names>M. N.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>T cell control of inflammaging</article-title>. <source>Semin. Immunol.</source> <volume>70</volume>, <fpage>101818</fpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2023.101818</pub-id>
<pub-id pub-id-type="pmid">37611324</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinert</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Vasan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chandel</surname>
<given-names>N. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mitochondrial metabolism regulation of T cell-mediated immunity</article-title>. <source>Annu. Rev. Immunol.</source> <volume>39</volume>, <fpage>395</fpage>&#x2013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-101819-082015</pub-id>
<pub-id pub-id-type="pmid">33902315</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Korner</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases</article-title>. <source>Front. Pharmacol.</source> <volume>9</volume>, <fpage>642</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.00642</pub-id>
<pub-id pub-id-type="pmid">29997500</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teissier</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Boulanger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>L. S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Interconnections between inflammageing and immunosenescence during ageing</article-title>. <source>Cells</source> <volume>11</volume> (<issue>3</issue>), <fpage>359</fpage>. <pub-id pub-id-type="doi">10.3390/cells11030359</pub-id>
<pub-id pub-id-type="pmid">35159168</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Contributions of age-related thymic involution to immunosenescence and inflammaging</article-title>. <source>Immun. Ageing</source> <volume>17</volume>, <fpage>2</fpage>. <pub-id pub-id-type="doi">10.1186/s12979-020-0173-8</pub-id>
<pub-id pub-id-type="pmid">31988649</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thorndike</surname>
<given-names>R. L.</given-names>
</name>
</person-group> (<year>1953</year>). <article-title>Who belongs in the family?</article-title> <source>Psychometrika</source> <volume>18</volume> (<issue>4</issue>), <fpage>267</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1007/BF02289263</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takiguchi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Phenotypic classification of human CD8&#x2b; T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function</article-title>. <source>Eur. J. Immunol.</source> <volume>34</volume> (<issue>4</issue>), <fpage>999</fpage>&#x2013;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200324478</pub-id>
<pub-id pub-id-type="pmid">15048710</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Aalderen</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>van Lier</surname>
<given-names>R. A. W.</given-names>
</name>
<name>
<surname>Hombrink</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>How to reliably define human CD8&#x2b; T-Cell subsets: markers playing tricks</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>13</volume> (<issue>11</issue>), <fpage>a037747</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a037747</pub-id>
<pub-id pub-id-type="pmid">33782028</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van den Broek</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Borghans</surname>
<given-names>J. A. M.</given-names>
</name>
<name>
<surname>van Wijk</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The full spectrum of human naive T cells</article-title>. <source>Nat. Rev. Immunol.</source> <volume>18</volume> (<issue>6</issue>), <fpage>363</fpage>&#x2013;<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-018-0001-y</pub-id>
<pub-id pub-id-type="pmid">29520044</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weyand</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Goronzy</surname>
<given-names>J. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Aging of the immune System. Mechanisms and therapeutic targets</article-title>. <source>Ann. Am. Thorac. Soc.</source> <volume>13</volume> (<issue>5</issue>), <fpage>S422</fpage>&#x2013;<lpage>S428</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201602-095AW</pub-id>
<pub-id pub-id-type="pmid">28005419</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Beyond T-cell subsets: stemness and adaptation redefining immunity and immunotherapy</article-title>. <source>Cell Mol. Immunol.</source> <volume>10</volume>, <fpage>957</fpage>&#x2013;<lpage>974</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-025-01321-7</pub-id>
<pub-id pub-id-type="pmid">40634636</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zwijnenburg</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Pokharel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Varnait&#x117;</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hoffer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shryki</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation</article-title>. <source>Immunity</source> <volume>56</volume> (<issue>8</issue>), <fpage>1955</fpage>&#x2013;<lpage>1974.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2023.06.025</pub-id>
<pub-id pub-id-type="pmid">37490909</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>